Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07070596

Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-celiac Enteropathies

Celiac disease is a chronic immune-mediated enteropathy triggered by gluten intake, which affects the small intestine in genetically susceptible subjects (HLA-DQ2 and/or HLA-DQ8). Affecting both children and adults, it is among the most common genetically determined disorders in Western countries. The disease is characterized by clinical manifestations (mainly digestive symptoms and signs of intestinal malabsorption), the presence of specific antibodies (tissue transglutaminase and endomysium) and enteropathy. Currently, the only treatment for celiac disease is a strict gluten-free diet for life.

The main objective of the NATURCEL registry (Study of the NATURal history, epidemiological, clinical, diagnostic and therapeutic aspects of celiac disease and non-celiac enteropathies) is to collect a wide range of data (epidemiological, clinical, genetic, immunological, etc.) for scientific and translational purposes.

The registry will include individuals diagnosed with celiac disease or other gluten-related disorders, as well as patients with non-celiac enteropathies evaluated for suspected celiac disease. In the future, the project also aims to establish a biobank-an organized repository of biological samples-to further support scientific and medical research in this field.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital Universitari MútuaTerrassa

Terrassa, Barcelona, 08221, Spain

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals under diagnostic evaluation for celiac disease

Exclusion criteria

  • Failure to sign informed consent

Treatment and study plan

Primary outcomes

  1. Proportion of patients with confirmed celiac disease diagnosis based on serologic and histologic criteria among those with suspected celiac disease

    Time frame: End of diagnostic evaluation (up to 10 weeks after inclusion)

Study contacts

Contact information is provided by the study sponsor or research team.

Albert Martín-Cardona, MD

CONTACT

[email protected]

(0034)937365050

Sponsors and collaborators

Lead sponsor

Hospital Mutua de Terrassa

Other

Collaborators

  • Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd)
  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
  • Hospital Arnau de Vilanova
  • Hospital Clinic of Barcelona
  • Hospital Universitari de Bellvitge

Registry information

Official study title

NATURCEL Registry: Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-celiac Enteropathies

Acronym: NATURCEL

Important dates

Study start
2025
Primary completion
2030
Study completion
2030
First posted
Jul 17, 2025
Registry last updated
Jul 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.